In a phase I study of locally advanced PDAC, the combination of PF-04136309 (an oral CCR2 inhibitor) and 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) resulted in a 49% ORR and a 97% DCR.80 However, an additional phase I/II study pairing the same oral CCR2 inhibitor with gemcitabine/nab-paclitaxel was terminated early because of lack of efficacy.81 A combinatory CCR2/CCR5 inhibitor with or without chemotherapy and anti–PD-1 therapy trial in metastatic colorectal and PDAC has finished enrollment with awaiting results (ClinicalTrials.gov identifier: NCT03184870). The gene discussed is CCR2; the disease is medical procedure.